STUDY протокол

A randomized trial to investigate the effects of pre-natal and infant nutritional supplementation on infant immune development in rural Gambia: the ENID trial: Early Nutrition and Immune Development

Sophie E Moore1,2*, Anthony JC Fulford1,2, Momodou K Darboe1, Modou Lamin Jobarteh1, Landing M Jarjou1 and Andrew M Prentice1,2

Abstract

Background: Recent observational research indicates that immune development may be programmed by nutritional exposures early in life. Such findings require replication from trials specifically designed to assess the impact of nutritional intervention during pregnancy on infant immune development. The current trial seeks to establish: (a) which combination of protein-energy (PE) and multiple-micronutrient (MMN) supplements would be most effective; and (b) the most critical periods for intervention in pregnancy and infancy, for optimal immune development in infancy.

Methods/Design: The ENID Trial is a 2 x 2 x 2 factorial randomized, partially blind trial to assess whether nutritional supplementation to pregnant women (from < 20 weeks gestation to term) and their infants (from 6 to 12 months of age) can enhance infant immune development. Eligible pregnant women from the West Kiang region of The Gambia (pregnancy dated by ultrasound examination) are randomized on entry to 4 intervention groups (Iron-folate (FeFol = standard care), multiple micronutrients (MMN), protein-energy (PE), PE + MMN). Women are visited at home weekly for supplement administration and morbidity assessment and seen at MRC Keneba at 20 and 30 weeks gestation for a detailed antenatal examination, including ultrasound. At delivery, cord blood and placental samples are collected, with detailed infant anthropometry collected within 72 hours. Infants are visited weekly thereafter for a morbidity questionnaire. From 6 to 12 months of age, infants are further randomized to a lipid-based nutritional supplement, with or without additional MMN. The primary outcome measures of this study are thymic development during infancy, and antibody response to vaccination. Measures of cellular markers of immunity will be made in a selected sub-cohort. Subsidiary studies to the main trial will additionally assess the impact of supplementation on infant growth and development to 24 months of age.

Discussion: The proposed trial is designed to test whether nutritional repletion can enhance early immune development and, if so, to help determine the most efficacious form of nutritional support. Where there is evidence of benefit from a specific intervention/combination of interventions, future research should focus on refining the supplements to achieve the optimal, most cost-effective balance of interventions for improved health outcomes.

Trial registration: ISRCTN49285450

* Correspondence: smoore@mrc.gm
1MRC Keneba, MRC Unit The Gambia, PO Box 273, Banjul, The Gambia
2MRC International Nutrition Group, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK

© 2012 Moore et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

General evidence for nutritional programming of immunity

A substantive and continually expanding body of observational evidence supports the thesis that nutritional exposures during pregnancy and/or early infancy may programme developing organ systems and homeostatic exposures during pregnancy and/or early infancy may program development of immune function. Rather than continue with this approach involving LNS to achieve nutritional repletion in late gestation and infancy, with consequent benefits in reducing vaccine failures and morbidity, and enhancing growth. The proposed design will specifically be able to test three exposures: (i) main effects due to each supplement; (ii) comparisons of main effects of different supplements; and (iii) effect modification of one supplement by another.

Methods/Design

Study design

The current trial has been designed to specifically investigate the effects of pre-natal and infant nutritional supplementation on infant immune development in rural Gambia, and has been given the acronym ENID: Early Nutrition and Immune Development. The ENID trial is a 2 × 2 × 2 factorial randomized partially blind trial of nutritional supplementation to pregnant women and their infants in the West Kiang region of The Gambia. Within the trial design, women are randomized to supplementation from when they book for antenatal care (<20 weeks gestation) until delivery and then their infants are further randomized from 6 to 12 months of age. The primary outcome measurements focus on infant immune development. Recruitment into the ENID trial started in early 2010, with the first infant born in August that year. It is anticipated that antenatal recruitment will be completed in December 2012, with the final infant reaching 12 months of age by approximately August 2014.

Setting and participants

The ENID Trial is based in the West Kiang region of The Gambia, a rural subsistence farming community of savannah and farmland, a roughly 750 km² rectangular tract of farmland bounded on 3 sides by the River Gambia and its tributaries. The trial is based in all 36 villages currently registered within the West Kiang Demographic Surveillance System (DSS; total resident population approximately 15,000). Following approval from the local community, all women of reproductive age (18 to 45 years) are invited to participate, and informed consent obtained. For the purpose of informed consent, a trained field worker explains the full details of the study to the subject, covering all aspects of the study as laid out in an information sheet. Illiterate
subjects additionally have the full information sheet read to them; literate subjects are given time to read the information sheet in their own time. Any questions that arise are then answered by the field worker, or referred to the principal investigator for clarification. Subjects are also given the possibility to speak to one of the study investigators (PI, study midwife, study clinician) if they wish. If the subject agrees to participate, written consent is obtained, through either a signature or thumb print. Women who are (i) currently pregnant (beyond 20 weeks on ultrasound assessment), (ii) currently enrolled in another MRC study, (iii) severely anaemic at booking (haemoglobin (Hb) less than 7 g/dL), or (iv) report the onset of menopause are excluded from entry into the trial.

Each month from enrolment participating women are visited by a member of the study team with a short questionnaire on the date of their last menstrual period (LMP). When a menses has been missed, a urine sample is collected for pregnancy testing using hCG tests (QuickVue™ One-Step hCG Urine Test, bioMérieux, UK). Women with a positive test are then invited to MRC Keneba for an ultrasound examination. Women confirmed as being between 10–20 weeks pregnant by ultrasound (using a Siemens ACUSON Antares Ultrasound Imaging System (Siemens Medical Solutions USA, Inc., California, USA) with a CH6-2 (5.71 MHz) transducer), are randomized into the trial, with supplementation commencing the following week.

The ENID Trial aims to have complete data for 800 mother-infant pairs. To account for losses to follow up (including those from withdrawals, out-migrations, pregnancy losses, infant deaths), ethical approval was obtained to recruit up to 1000 pregnant women, to allow for a maximum attrition rate of 20%. We anticipate, however, that fewer than 1000 women will need to be recruited, as the West Kiang population is highly motivated for participation in research projects.

The trial is approved by the joint Gambia Government / MRC The Gambia Ethics Committee (Project number SCC1126v2). The trial is monitored by an Independent Trial Monitor (ITM; Dr Karen Edmond, London School of Hygiene and Tropical Medicine) and a Data Safety Monitor (DSM; Dr Kalifa Bojang, Royal Victoria Teaching Hospital, Banjul, and MRC Unit, The Gambia). The primary role of the ITM is to monitor adherence to the trial protocol and to supervise the progress of the trial toward its objectives. The DSM will conduct interim analyses of the safety data, by randomization group, pertaining to the occurrence of Adverse Events (AE); (i) following recruitment of one half of antenatal cases, (ii) on completion of antenatal recruitment, and (iii) once half the infants have reached the final point in the trial, at 12 months of age. In addition, reports on Serious Adverse Events (SAE) are submitted to the DSM in real time. The trial will be stopped in the case of (A) any unexpected SAE (such as a severe/fatal allergic reaction to any one of the trial supplements) or (B) a consistent pattern of SAEs and/or AEs within one or more arms of the trial, and following the direction of both the DSM and ITM. No interim analyses on the outcome data are planned.

**Intervention - pregnancy**

At booking eligible women are randomized to one of four intervention arms: 1.) Iron-folate (FeFol), representing the usual standard of care during pregnancy, as per Gambian Government guidelines; 2.) Multiple micronutrients (MMN), a combination of 15 micronutrients, specifically designed for use during pregnancy, and as formulated by UNICEF/WHO/UNU. A single tablet provides the Recommended Dietary Allowance (RDA) for each micronutrient. However, in view of evidence to suggest that in this region a daily supplement of twice the RDA is more effective with regard to birth outcomes [17], women in this arm of the trial are supplemented at $2 \times$ RDA (but with the same level of iron and folate to the FeFol arm). Both the FeFol and MMN supplements are formulated as tablets and manufactured by Scanpharm, Denmark (www.scanpharm.dk). 3.) Protein-energy and iron-folate (PE + FeFol), a lipid based nutritional supplement (LNS) providing the same level of iron and folate to the FeFol only arm, but with the addition of energy, protein and lipids. 4.) Protein-energy and multiple micronutrients (PE + MMN), a micronutrient fortified LNS supplement providing the same level of micronutrients to the MMN arm (including FeFol), in addition to the energy and protein and lipid content. The two LNS products are manufactured by Valid Nutrition, Nairobi, Kenya (www.validinternational.org). The composition of the four pre-natal supplement groups is as detailed in Table 1.

**Randomization and allocation**

Randomization into the trial is in blocks of 8, using an automated system, with the 8 groups reflecting the 8 combinations of prenatal and infancy supplements (Figure 1). Once randomized, the code allocated to each mother will remain the same for her infant. Allocation of each supplement combination to a number between 1 and 8 was performed by Dr Mathilde Savy (IRD, France), with this information passed directly to the supplement manufacturers. Each box of supplement is then distinguished by a number between 1 and 8. An additional hard copy of the code assignment is held in the safe in Keneba, accessible by the field station senior administrator and only at the request of the trial monitors. The antenatal arm of the trial is partly open, since it is not be possible to
Table 1 Nutritional composition of daily intake of pregnancy supplements

|          | Tablets FeFol | MMN | PE + FeFol | PE + MMN |
|----------|---------------|-----|------------|----------|
| Iron (mg)| 60            | 60  | 60         | 60       |
| Folate (μg)| 400        | 400 | 400        | 400      |
| Vitamin A (RE μg)| 1600 | 2.85  | 1600      |
| Vitamin D (IU)| 400     | -   | 400        |
| Vitamin E (mg)| 20       | 4.2  | 20         |
| Vitamin C (mg)| 140      | 2.25 | 140        |
| Vitamin B1 (mg)| 2.8      | 0.3  | 2.8        |
| Vitamin B2 (mg)| 2.8      | 0.45 | 2.8        |
| Niacin (mg)| 36          | 1.35 | 36         |
| Vitamin B6 (mg)| 2.8      | 0.15 | 2.8        |
| Vitamin B12 (μg)| 5.2     | 0.1  | 5.2        |
| Zinc (mg)| 30           | 3.3  | 30         |
| Copper (mg)| 4          | 1.05 | 4          |
| Selenium (μg)| 130      | 6.15 | 130        |
| Iodine (μg)| 300         | 2.6  | 300        |
| Energy (kcal)| 746        | 746  | 746        |
| Protein (g)| 20.8        | 20.8 | 20.8       |
| Lipids (g)| 52.6        | 52.6 | 52.6       |

Data in italics represent MMN content from base ingredients.

Table 1: Nutritional composition of daily intake of pregnancy supplements.

All resident women of reproductive age → Consent ing women who fall pregnant → Randomization at booking to pre-natal supplement → FeFol N=250, MMN N=250, PE N=250, PE+MMN N=250 → Randomization at 6 month of age to MMN fortified weaning food or placebo → LNS N=125, +MMN N=125, LNS N=125, +MMN N=125, LNS N=125, +MMN N=125, LNS N=125, +MMN N=125

Figure 1: Trial design.
status, plus samples of serum, plasma and DNA are biobanked for future analyses. Fetal ultrasound: Fetal biometry by ultrasound (Siemens ACUSON, as above), including bi-parietal diameter, occipital frontal diameter, head circumference, abdominal circumference and femur and tibia length.

In this community, the majority of women choose to deliver in their homes with the support of a Traditional Birth Attendant (TBA). Through a network of posted field workers, we attempt to attend all deliveries occurring in West Kiang. Following delivery a sample of cord blood (15 mL) is collected and the placenta transported on ice to the MRC Keneba laboratory for processing. On arrival, cord blood samples are processed and placental material is collected for the assessment of placental micronutrient transport proteins.

Within 72 hours of delivery, all women and their newborn infants are visited by one of the study midwives for a ‘baby check’, which includes infant anthropometry (weight, length, MUAC, head circumference), gestational age assessment by Dubowitz score [18] and a general health check. Neonates assessed as unwell are referred to the MRC Keneba clinic for assessment by the study clinician/resident paediatrician.

Intervention - infancy

In The Gambia, exclusive breastfeeding to six months of age is recommended and the National Nutrition Agency (NaNA) actively promotes this practice to the population. Community-based peer counselling in exclusive breastfeeding has proven efficacious in improving both the rate and duration of exclusive breastfeeding [19,20]. Within the ENID Trial, we will work with NaNA to train community health nurses to promote exclusive breastfeeding for all participating women. The purpose of this element of the study is to ensure that all women are provided with the knowledge to provide optimal nutrition to their infants during the period from birth to 6 months of age.

Between birth and six months of age, infants are visited weekly for the collection of morbidity data by questionnaire. From six months of age, infants commence supplementation with either an unfortified LNS paste or the same LNS formulation fortified with multiple micronutrients. The nutritional composition of both products is as detailed in Table 2. This arm of the trial is double blind, with infants receiving identically packaged formulations prepared in individually labeled plastic containers. Supplements are distributed to mothers on a weekly basis, and the mother is asked to administer the supplement/placebo on a daily basis by mixing 20 g of the LNS product with the infant’s normal weaning food. Identical spoons are provided to mothers, to encourage that a uniform amount is given to each infant, per day. Mothers are asked to give the study infant the full dose, and compliance is assessed through random spot checks and by a questionnaire administered on a weekly basis. At these weekly visits, a morbidity questionnaire is also completed for each infant.

Scheduled infancy measurements and sample collection details

Following delivery, infants are seen at the MRC Keneba field station when they are 1, 8, 12, 24 and 52 weeks of age, with additional home visits at 16, 20, 32 and 40 weeks of age. Table 3 details the data and sample collection schedule for each visit. At all time points, detailed measures of infant anthropometry are taken using standard protocols with regularly validated equipment. Measurements include weight, length, knee-heel length, head circumference, abdominal circumference, chest circumference, thigh circumference, MUAC, and triceps, biceps, subcapular, suprailiac and thigh skinfold thickness. At all visits in Keneba, a 5 mL sample of breast milk is also collected from each breast, for

| Nutrient | PE | PE + MMN |
|----------|----|---------|
| β-Carotene (μg RE) | 1.84 | 400 |
| Vitamin C (mg) | 1.88 | 30 |
| Folic acid (μg) | 13.1 | 80 |
| Thiamine (mg) | 0.06 | 0.3 |
| Riboflavin (mg) | 0.04 | 0.4 |
| Vitamin B3 (mg) | 0.32 | 4 |
| Pantothenic acid (mg) | 0.08 | 1.8 |
| Vitamin B6 (mg) | 0.02 | 0.3 |
| Vitamin B12 (μg) | 0.06 | 0.5 |
| Vitamin D (μg) | 0.34 | 5 |
| Vitamin E (mg) | 0.12 | 2.7 |
| Vitamin K (μg) | 1.40 | 10 |
| Iron (mg) | 0.46 | 9 |
| Zinc (mg) | 0.24 | 4 |
| Calcium (mg) | 33.1 | 100 |
| Potassium (mg) | 91.76 | 152 |
| Copper (mg) | 0.02 | 0.2 |
| Selenium (μg) | 1.44 | 10 |
| Iodine (μg) | 1.40 | 90 |
| Phosphorus (mg) | 42.56 | 82 |
| Magnesium (mg) | 14.56 | 16 |
| Manganese (mg) | 0.08 | 0.08 |
| Total energy (kcal) | 108 | 108 |
| Linoleic acid (g) | 1.29 | 1.29 |
| Linolenic acid (g) | 0.29 | 0.29 |

Data in italics represent MMN content from base ingredients.
the assessment of breast milk micronutrient levels and residual samples frozen at −80°C for long term storage. Milestones of Gross Motor Development are assessed monthly, from when the child is six months of age [21]. At 12 months of age, parental anthropometry is taken and a socio-economic questionnaire completed.

Study personnel administer EPI vaccines to all infants, as per Gambian government protocol (Table 4). All study vaccines are acquired direct from the EPI Department of the Gambia Government, and the cold-chain managed thereafter by the study team. At 12, 24 and 52 weeks of age, a venous blood sample is collected from infants for the assessment of antibody response to vaccination, micronutrient status, with residual aliquots biobanked for further biomarker measurements. Cord blood and samples from 12 and 24 week bleeds will be used to assess anti-diphtheria, tetanus toxoid, Haemophilus B Influenzae, OPV and Hepatitis B antibody titres will be measured. In cord, 24 week and 52 week samples, measles antibody levels will be assessed. DNA samples for both mother and infant are collected and held within the Keneba Biobank.

Thymus size is assessed sonographically at 1, 8, 24 and 52 weeks using a validated method in which the transverse diameter of the thymus and the sagittal area of its largest lobe are multiplied to give a volume-related thymic index (TI) [22]. The human thymus is a primary lymphoid organ essential for the establishment of a normal peripheral T-lymphocyte immune system. Whilst little data exists to support TI as a robust measure of immunocompetence, TI has been shown to correlate with thymus weight at autopsy and has been previously by our group both in Keneba and in Bangladesh to show that the human thymus is sensitive to environmental influences during infancy [8]. Thymus size will be measured using a Siemens Acuson ultrasound unit together with a P10-4 Transducer (Siemens, UK). To further validate the significance of TI and to understand the cellular basis of any observed alterations in antibody response, we will measure cellular markers of immunity in a sub-sample of the cohort (one full calendar year of births), using samples of infant blood collected at 12, 24 and 52 weeks of age.

**Study outcomes**

The primary outcome measure for this study is TI. As with previous datasets on thymic development [9] we will assess the impact of the interventions on TI at the different time points (week 1, 8, 24 & 52) separately, and on the time points pooled. These separate analyses are deemed necessary, since the different time points reflect different exposures (week 1 measurements reflecting prenatal supplementation only, week 52 reflecting combined pre- and post-natal interventions). Secondary outcomes include (i) antibody response to vaccination and (ii) detailed cellular immunology (on a subset of infants only).

**Analytical plan**

The ENID Trial aims to have complete data on a total of 800 mother-infant pairs. There are three types of questions that the proposed study will address:

(i) Main effects due to each supplement (i.e. supplement vs. placebo (usual care; FeFol only)).
(ii) Comparison of main effects of different supplements (i.e. supplement A vs. supplement B).
(iii) Effect modification of one supplement by another.

In each case we consider analysis of both (a) the full data set (i.e. all combinations of treatment A, B & C; subgroups 1–8 in Table 5) and (b) also (in order to avoid possible interference from interactions) in the subset of subjects who did not receive any supplements.
other than that/those involved in the particular hypothesis under test.

(a) When considering questions (i) and (ii) analyzing the full dataset we fit the model:
\[ Y_i = \beta_0 + \beta_A A_i + \beta_B B_i + \beta_C C_i + \epsilon_i \]
For question (i) we will test the significance of \( \beta_A \), \( \beta_B \) and \( \beta_C \); for question (ii) we examine the contrasts \( \beta_A - \beta_B \), \( \beta_A - \beta_C \) and \( \beta_B - \beta_C \).

When employing the full data set to consider the first order interactions between two treatments – question (iii) – we would fit the model including all these interactions:
\[ Y_i = \beta_0 + \beta_A A_i + \beta_B B_i + \beta_C C_i + \beta_{AB} A_i B_i + \beta_{AC} A_i C_i + \beta_{BC} B_i C_i + \epsilon_i. \]
We would then test the significance of \( \beta_{AB} \), \( \beta_{AC} \) and \( \beta_{BC} \). For completeness we would also fit the second order interaction between A, B & C using the model below, although the study is not powered for that.
\[ Y_i = \beta_0 + \beta_A A_i + \beta_B B_i + \beta_C C_i + \beta_{AB} A_i B_i + \beta_{AC} A_i C_i + \beta_{BC} B_i C_i + \beta_{ABC} A_i B_i C_i + \epsilon_i. \]

(b) The subset of data used to fit the main effect of treatment A (say) would include only subgroups 1 and 2 and fit the model:
\[ Y_i = \beta_0 + \beta_A A_i + \epsilon_i. \]

To compare treatment A with B excluding interference from C we would use subgroups 1–3 and 5 and fit the model:
\[ Y_i = \beta_0 + \beta_A A_i + \beta_B B_i + \epsilon_i. \]
Finally, to examine the interaction between treatment A and B excluding interference from C we would employ the same subgroups (1–3 & 5) and fit the model:
\[ Y_i = \beta_0 + \beta_A A_i + \beta_B B_i + \beta_{AB} A_i B_i + \epsilon_i. \]

The primary outcome measurement (thymic index, TI) will be made on infants of different sizes and ages. We will therefore carry out the analysis on the logarithm of the TI measurements since the (a) percentage changes are more appropriate, (b) the standard deviation is then essentially independent of the mean and (c) the residual distribution is more symmetrical. Otherwise the analysis will be based on least-squares regression controlling for infant size and season of observation and other covariates that have a noticeable effect on the variance.

Since three treatments or three pairs of treatments are under consideration for each of the above questions we have applied a Bonferroni correction for the best of three tests.

Table 6 gives the required numbers to achieve a power of 80% with significance level of 5%. The different columns correspond to the different questions listed above. The effect sizes considered are similar to those previously observed between seasons [8]. We also assume that between individuals the sd[log(TI)] = 0.21, which is the standard deviation of the residuals after controlling for infant size and season of observation derived from Collinson et al’s data [8].

**Discussion**
The ENID Trial has been designed to investigate the impact of combined pre- and post-natal nutritional supplementation on immune development in Gambian infants. The trial design will specifically allow us to establish which combination of supplements is most effective and also the most critical periods of intervention in pregnancy and

### Table 5 Treatment combinations

| Subgroup | A | B | C |
|----------|---|---|---|
| 1        | 0 | 0 | 0 |
| 2        | 1 | 0 | 0 |
| 3        | 0 | 1 | 0 |
| 4        | 0 | 0 | 1 |
| 5        | 1 | 1 | 0 |
| 6        | 1 | 1 | 1 |
| 7        | 0 | 1 | 1 |
| 8        | 1 | 1 | 1 |

### Table 6 Sample size required for a range of effect sizes and different hypotheses to be tested

| Effect size (% difference in TI) | (i) Main effects of treatments versus placebo | (ii) Comparison of pairs of main effects versus one another | (iii) Interactions between pairs of treatments |
|---------------------------------|---------------------------------------------|-------------------------------------------------------|-----------------------------------------------|
|                                 | Full dataset | Reduced dataset* | Full dataset | Reduced dataset* | Full dataset | Reduced dataset* |
| 5%                              | 847          | 3388             | 1694         | 3388             | 3388         | 6776               |
| 7.5%                            | 385          | 1542             | 771          | 1542             | 1542         | 3084               |
| 10%                             | 222          | 888              | 444          | 888              | 888          | 1776               |

* Avoiding interference from irrelevant treatment.
infancy, and whether any observed effects are additive. To date, there are no previous registered or published trials on this topic. Previous trials of MMN [23] and PE [24] interventions in pregnancy have concentrated almost exclusively on birth weight and perinatal survival as outcomes. A single trial (in HIV-infected mothers) has investigated a limited range of T-cell subsets in pregnancy, but not in the offspring, and found that limited MMN supplementation (vitamins B, C and E), but not vitamin A alone, increased CD4+ and CD8+ counts [25]. The ENID Trial will also provide valuable data on other important developmental markers including growth.

Where there is evidence of benefit from a specific intervention/combination of interventions, future research should focus on refining the supplements to achieve the optimal, most cost-effective balance of interventions for improved health outcomes. Findings may also precipitate a separately funded larger or multicentre trial with morbidity and/or mortality as the primary outcome. Where evidence indicates a defect in a specific component/components of immune function, more detailed interrogation within a subset of subjects from follow-up trials, likely to involve more intense sample collection schedules, will be justified, and will help to further our understanding of specific interactions. In the event that none of the supplementation combinations under trial have a marked impact on immune development across the whole cohort, data obtained may help pinpoint specific vulnerable groups (such as women with low pre-pregnancy BMI’s for whom intervention may be most efficacious), for further targeted research.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SEM, AJCF, MKD, LMJ, MLJ, & AMP all contributed to the development of the trial protocol. SEM drafted this manuscript and all authors reviewed critically. SEM, AJCF, MKD, LMJ, MLJ, & AMP all contributed to the development of the trial protocol. SEM drafted this manuscript and all authors reviewed critically.

Acknowledgements
This trial is supported through by the Medical Research Council (UK), through core funding to the MRC International Nutrition Group (MC-A760-SQX00).

Received: 15 February 2012 Accepted: 31 August 2012 Published: 11 October 2012

References
1. Barker DJP. Mothers, Babies and Diseases in Later Life. London: BMJ Publishing Group; 1994.
2. Moore SE, Collinson AC, Tambia Ngom P, Aspinall R, Prentice AM: Early immunological development and mortality from infectious disease in later life. Proc Nutr Soc 2006, 65(3):311–318.
3. Prentice AM, Whitehead RG, Roberts SB, Paul AA: Long-term energy balance in childbearing Gambian women. Am J Clin Nutr 1981, 34:2790–2799.
4. Rayco-Solon P, Fulford AJ, Prentice AM: Maternal preconceptional weight and gestational length. Am J Obstet Gynecol 2005, 192(4):1133–1136.
5. Rayco-Solon P, Fulford AJ, Prentice AM: Differential effects of seasonality on preterm birth and intrauterine growth restriction in rural Africans. Am J Clin Nutr 2005, 81(1):134–139.
6. Moore SE, Cole TJ, Collinson AC, Poskitt EME, McGregor IA, Prentice AM: Prenatal or early postnatal events predict infectious deaths in young adulthood in rural Africa. Int J Epidemiol 1999, 28:1088–1095.
7. Moore SE, Cole TJ, Poskitt EME, Sanko BJ, Whitehead RG, McGregor IA, et al: Season of birth predicts mortality in rural Gambia. Nature 1997, 388:434.
8. Collinson AC, Moore SE, Cole TJ, Prentice AM: Birth season and environmental influences on patterns of thymic growth in rural Gambian infants. Acta Paediatr 2003, 92(9):1014–1020.
9. Moore SE, Prentice AM, Wayatasuma Y, Fulford AJ, Collinson AC, Raqib R, et al: Early-life nutritional and environmental determinants of thymic size in infants born in rural Bangladesh. Acta Paediatr 2009, 98(7):1166–1175.
10. Collinson AC, Ngom PT, Moore SE, Morgan G, Prentice AM: Birth season and environmental influences on blood leucocyte and lymphocyte subpopulations in rural Gambian infants. BMC Immunol 2008, 9:18.
11. NGom PT, Collinson AC, Pido-Lopez J, Henson SM, Prentice AM, Aspinall R: Improved thymic function in exclusively breastfed infants is associated with higher interleukin 7 concentrations in their mothers’ breast milk. Am J Clin Nutr 2004, 80:722–728.
12. McDade TW, Beck MA, Kuzawa CW, Adair LS. Prenatal undernutrition, postnatal environments, and antibody response to vaccination in adolescence. Am J Clin Nutr 2001, 74(4):543–548.
13. Moore SE, Jail F, Ashraf R, Szu SC, Prentice AM, Hanson LA: Birth weight predicts response to vaccination in adults born in an urban slum in Lahore, Pakistan. Am J Clin Nutr 2004, 80:453–459.
14. Moore SE, Jail F, Szu SC, Hahn-Zoric M, Prentice AM, Hanson LA: Revaccination does not improve an observed deficit in antibody responses in Pakistani adults born of a lower birth weight. Vaccine 2008, 26(2):158–165.
15. Adu-Afarwuah S, Larney A, Brown KH, Zlotkin S, Briend A, Dewey KG: Randomized comparison of 3 types of micronutrient supplements for home fortification of complementary foods in Ghana: effects on growth and motor development. Am J Clin Nutr 2007, 86(2):412–420.
16. Briend A, Solomon NW. The evolving applications of spreads as a FOODIet for improving the diets of infants and young children. Food Nut Bull 2003, 24(3):534–538.
17. Kaestel P, Michaelisen KF, Aaby P, Fris H: Effects of prenatal multimicronutrient supplements on birth weight and perinatal mortality: a randomised, controlled trial in Guinea-Bissau. Eur J Clin Nutr 2005, 59(9):1081–1089.
18. Dubowitz LM, Dubowitz V, Palmer P, Verghote M: A new approach to the neurological assessment of the preterm and full-term newborn infant. Brain Dev 1980, 2(13):14.
19. Albemarz E, Victoria CG, Haima H, Wright A, Coward WA: Lactation counseling increases breast-feeding duration but not breast milk intake as measured by isotopic methods. J Nutr 2003, 133(1):205–210.
20. Haider R, Ashworth A, Kabir I, Huttly SR. Effect of community-based peer counsellors on exclusive breastfeeding practices in Dhaka, Bangladesh: a randomised controlled trial [see comments]. Lancet 2000, 356(9242):1643–1647.
21. WHO Motor Development Milestones. [cited 2012 14th February]. Available from: http://www.who.int/childdown/standards/motor_milestones/en/index.html.
22. Hasselbalch H, Nielsen MB, Jeppsen D, Pedersen JF, Karkov J: Sonographic measurement of the thymus in infants. Eur Radiol 1996, 4(7):700–703.
23. Haider BA, Bhutta ZA: Multiple-micronutrient supplementation for women during pregnancy. Cochrane Database Syst Rev 2005, 4(2):CD004905.
24. Kramer MS, Kakuma R: Energy and protein intake in pregnancy. Cochrane Database Syst Rev 2003, 4(2):CD000302.
25. Fawzi WW, Msamanga GI, Spiegelman D, Wei R, Kapiga S, Villamor E, et al: A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004, 351(1):23–32.

doi:10.1186/1471-2393-12-107

Cite this article as: Moore et al.: A randomized trial to investigate the effects of pre-natal and infant nutritional supplementation on infant immune development in rural Gambia: the ENID trial: Early Nutrition and Immune Development. BMC Pregnancy and Childbirth 2012:12:107.